Last week, The Lawyer reported on Pfizer’s $160bn merger with Allergan, in which over 10 firms are acting on one of the largest healthcare transactions in history.

But at least the in-house teams didn’t have to contend with a merger, injunction attempt, simultaneous de-listing and new listing all in one year.

These were exactly the challenges faced by LivaNova’s general counsel Brian Sheridan, whose company was formed following the merger of pharmaceutical companies Sorin and Cyberonics, announced last February.

He explained how his in-house team worked with a number of firms in both the US and Italy, including Latham & Watkins, Gianni Origoni Grippo Cappelli & Partners, Sullivan & Cromwell and Legance.

From February onwards, negotiations were held in which Sorin and Cyberonics were delisted from the Italian and US stock exchanges respectively, while the companies were then merged to create LivaNova.

The latter was subsequently listed back onto the NASDAQ as well as the London Stock Exchange “to reflect what’s happening in the life sciences sphere”.

Also on

Featured briefings
Gateley – Moving the goalposts on penalty clause shoot-outs
Carey Olsen – Why incorporate a start-up in the BVI?
Shoosmiths – Tax update: enterprise investment scheme and venture capital trust changes
First Names (Jersey) Limited – PE: bane or blessing?
Gateley – Insolvency: it’s a matter of principle